Christopher Pierce

Christopher Pierce is the SVP, Corporate & Product Strategy at Treeline Biosciences. Prior to joining Treeline, Christopher served as the Executive Vice President, Chief of Business Operations at Prelude Therapeutics Incorporated from July 2020 to September 2021. At Prelude, Christopher led corporate development activities including investor & public relations, business development, competitive intelligence, portfolio / pipeline strategy, and new product planning.

Previously, Christopher was the VP, Head of Commercial at Loxo Oncology, Inc. from April 2017 to May 2019. At Loxo Oncology, Christopher built and oversaw the commercial organization, with broad responsibilities across Marketing, Market Access, Trade/Distribution, Commercial Insights & Analytics, Operations, and Field Force. During their time at Loxo Oncology, Christopher led the launch of VITRAKVI (larotrectinib), in co-promote partnership with Bayer, as well as all commercialization activities for LOXO-292.

Before joining Loxo Oncology, Christopher was the Senior Director / Global Commercial Lead, Hematologic Malignancies Portfolio at Pfizer from August 2008 to March 2017. In this role, Christopher was responsible for the global commercial strategy and execution for the hematologic malignancies portfolio.

Christopher began their career at Pfizer as a Summer Marketing Associate in the WW Oncology group from June 2007 to August 2007.

Christopher Pierce earned their MBA from Harvard Business School and their AB from Harvard University in Biochemical Sciences.

Christopher Pierce reports to Joshua Bilenker, CEO & Co-Founder. They work with Spencer Smith - SVP, Corporate Development, Sara Shulman - VP, Preclinical Operations, and Jennifer Taylor - SVP, Portfolio & Science Operations.